Sanctura: profile and news

Indevus Pharmaceuticals Scheduled to Present at Rodman & Renshaw ...  May 11, 2006
The Company currently markets SANCTURA(R) for overactive bladder and DELATESTRYL(R) for the treatment of male hypogonadism. The ... - Genetic Engineering News,

Indevus Announces Second Quarter Fiscal 2006 Financial Results ...  May 8, 2006
..."We completed enrollment in both Phase III clinical trials for SANCTURA XR(TM) as well as our Phase II pagoclone trial for stuttering. ... - Genetic Engineering News,

Indevus Pharma credits healthier drug sales for Q2 boost  May 9, 2006
...company said revenue was $14.4 million, up from $9.3 million in the second quarter of 2005, primarily driven by sales and royalties of Sanctura, a treatment ... - San Antonio Business Journal,

Indevus Pharmaceuticals to Announce Second Quarter Fiscal 2006 ...  May 2, 2006
The Company currently markets SANCTURA® for overactive bladder and DELATESTRYL® for the treatment of male hypogonadism. The Company ... - Market Wire (press release)

Tricare co-pay to increase for six brand-name drugs  Apr 26, 2006
The new prices for these medications will take effect July 26. • Detrol, Oxytrol and Sanctura, used to treat overactive bladder conditions. ... - ArmyTimes.com,